Direct compression screening of 2-hydroxybenzimidazole as an oral tablet starts with powder flow, wall friction angle, and compressibility rather than chemical purity alone. Batches from different synthetic routes may differ in crystal habit enough to shift the flow function coefficient by an order of magnitude. The API is assessed by USP <616> bulk and tapped density, USP <1174> powder flow, and Ph. Eur. 2.9.36 flow rate. A representative starting core for a 50.0 mg strength tablet contains 50.0% w/w API, 32.5% w/w microcrystalline cellulose, 15.0% w/w lactose monohydrate, 2.0% w/w croscarmellose sodium, and 0.5% w/w magnesium stearate. Pre-mixing the API with an equal portion of microcrystalline cellulose is required when the particle size D90 exceeds 150 µm because segregation in the feed frame has been observed on rotary presses operating above 60 rpm. Compression force is maintained between 8 kN and 16 kN. Compact tensile strength should remain above 1.5 MPa to control lamination. Ejection force is monitored because shear-induced heating at the die wall can create a surface layer that reduces tablet hardness and raises friability above 1.0%. The terminal product is an immediate-release uncoated tablet subject to USP <905> content uniformity, USP <711> dissolution, and ICH Q3D elemental impurity assessment. Published data for this specific API in direct compression is limited, so the ratios given are representative starting points and need confirmation by design of experiments. The processing window narrows if blend moisture exceeds 2.5% w/w. Lubrication with magnesium stearate above 1.0% w/w may extend disintegration beyond 15 minutes in purified water at 37 °C, which conflicts with an immediate-release target. Lubrication is therefore limited to 3 minutes in a V-blender at 25 rpm.

What Limits Fill Weight Variability in Low-Dose 2-Hydroxybenzimidazole Hard Capsule Blends?

Low-dose hard capsule filling for 2-hydroxybenzimidazole depends on the coefficient of variation of the pre-blend before the capsule machine starts. A representative 10.0 mg strength two-piece hard gelatin capsule uses a 200 mg fill weight. The API fraction is 10.0% w/w. The carrier blend comprises 72.5% w/w mannitol, 15.0% w/w microcrystalline cellulose, 2.0% w/w sodium starch glycolate, and 0.5% w/w sodium stearyl fumarate. Fill weight variability should remain below 3.0% RSD at a machine speed of 60,000 capsules/hour on a dosing-pin capsule filler. The critical process parameter is not only bulk density but also the angle of internal friction of the lubricated blend. Dosing pins are replaced at 8-hour intervals in continuous manufacturing because build-up on pin tips causes weight drift. A second pre-mix step with a 5:1 diluent-to-API ratio is required when the API D90 exceeds 100 µm. Gelatin capsule shells are equilibrated to 45–55% RH to avoid brittle fracture at the lower end and softening at the upper end. The terminal dosage form is a hard gelatin capsule tested against USP <905> content uniformity and USP <2040> disintegration. Dissolution in 0.1 N hydrochloric acid is controlled primarily by de-aggregation rather than intrinsic API solubility. Compatibility with gelatin must be confirmed because residual aldehydes in the shell can induce crosslinking if the imidazole nitrogen at the particle surface reacts with the shell matrix. Crosslinking is detected as a hydrated film during USP <711> dissolution with enzyme media. If pellicle formation is observed, the shell is changed to HPMC capsules. Published absolute bioavailability data across different capsule formulations of this API is limited, so the formula is intended for early-phase clinical trial supplies.

High-Shear Impeller Wet Granulation and the Binder Liquid Window for 2-Hydroxybenzimidazole

Wet granulation of 2-hydroxybenzimidazole is selected only when direct compression or dry granulation shows insufficient compactibility. The granulating liquid is purified water because organic solvents create Class 2 solvent residue obligations under ICH Q3C. A representative dry blend contains 20.0% w/w API, 64.0% w/w lactose monohydrate, 10.0% w/w povidone K30, and 6.0% w/w crospovidone. Povidone K30 is pre-dissolved in water to form a 5.0% w/w binder solution. Liquid addition rate is set at 15 mL/min per 1 kg dry powder. End-point is controlled by impeller torque, not by a fixed volume. Torque target corresponds to granule moisture of 4.0–6.0% w/w. Granules are wet milled through a 1.0 mm screen, dried in a fluid bed at 60 °C inlet air temperature until moisture is below 2.0% w/w. Drying above 70 °C has produced surface discoloration when the API partially hydrates. The terminal granules are filled into sachets or compressed into tablets after blending with 0.8% w/w magnesium stearate. A hard failure mode occurs if the binder solution is added too quickly. Local overwetting produces dense granules with D50 above 800 µm, and subsequent sachet filling fails content uniformity. End-point control therefore uses a time-averaged torque curve rather than single-point power measurement. Batch-to-batch repeatability on the same GEA PMA 25 high-shear granulator is the primary scale-up parameter. Granules are tested against Ph. Eur. 2.9.12 particle size distribution and USP <786> analytical sieving.

Injectable application of 2-hydroxybenzimidazole as a sterile lyophilized powder begins with solubility screening in water-for-injection, phosphate buffer at pH 6.8, and 0.9% sodium chloride. Published intrinsic solubility data for this API is limited, so screening under ICH Q3C solvent options must cover PEG 300, propylene glycol, and sulfobutylether-β-cyclodextrin. A representative lyophilization formulation is a solution at 5.0 mg/mL API in 20% w/w sulfobutylether-β-cyclodextrin and 2.5% w/w mannitol as bulking agent. The solution is passed through a 0.22 µm PVDF membrane. Filtration recovery should be not less than 95.0% to avoid filter adsorption. Filling volume is 10 mL per 20 mL tubing vial. The freeze-dry cycle holds shelf temperature at -40 °C for 2 hours, primary drying at -20 °C and 80 mTorr, and secondary drying at 25 °C for 6 hours. The lyophilized cake should contain moisture below 1.0% w/w and reconstitute with 10 mL WFI in 30 seconds. The terminal product is a sterile powder for injection. Release testing includes USP <71> sterility, USP <85> bacterial endotoxins, USP <788> particulate matter in injections, and 21 CFR 211.94 container closure evaluation. The main operational boundary is pH shift. 2-Hydroxybenzimidazole may undergo keto-enol tautomerization at low pH, and lyophilization from unbuffered solutions can produce cake collapse if the formulation pH drifts below 3.0 during freezing.

When Terminal Sterilization Cannot Be Applied to 2-Hydroxybenzimidazole Injectable Solutions

Terminal sterilization by autoclave at 121 °C for 15 minutes is evaluated first for injectable solutions because it provides the highest sterility assurance level. For 2-hydroxybenzimidazole, thermal degradation studies in aqueous solution at 80 °C, 100 °C, and 121 °C are run before any registration decision. If degradation exceeds 0.5% total impurities at 121 °C for 15 minutes compared with the starting material, terminal sterilization is rejected. The alternative is aseptic filtration through a 0.22 µm membrane into sterile vials inside an isolator or restricted access barrier system. The fill-finish line must maintain Grade A airborne particles at ≤ 2,520 particles/m³ for ≥ 0.5 µm particulate under ISO 14644-1 Class 5. Aseptic holding time between the first and last fill must not exceed 6 hours unless bioburden is monitored every 2 hours. A representative solution is prepared at 10 mg/mL in 10 mM phosphate buffer at pH 7.0 with 0.9% sodium chloride. The terminal product is a ready-to-use injectable solution in 10 mL Type I borosilicate glass vials. Release tests include USP <71> sterility, USP <85> endotoxin limit ≤ 0.25 EU/mg, USP <788> subvisible particles, and USP <1207> container closure integrity. Published data for thermal stability in the presence of phosphate buffer is limited, so the autoclave rejection decision must be based on forced degradation data generated on the actual batch. Incompatibility with rubber stopper components requires extraction studies under USP <381> before stability batches are committed.

Sachet-Grade Granules Are Controlled by a Different Particle Size Window than Tableting Granules

Oral granules packed into single-dose sachets are not a direct by-product of tableting because tableting granules can be too coarse for uniform volumetric filling. For sachet application, 2-hydroxybenzimidazole granules are prepared with 25.0% w/w API, 62.0% w/w sucrose spheres as starter cores, 8.0% w/w low-substituted hydroxypropylcellulose, 3.0% w/w talc, and 2.0% w/w PEG 6000. Final granule size is targeted at 100–300 µm D50 so the product flows through a vertical sachet filler auger without bridging. Each sachet contains 250 mg granules, equivalent to a 50 mg dose when potency is 200 mg/g. Auger filling with net weight control must keep fill weight variation within ±5.0% per sachet. Moisture specification is tightened to 1.5% w/w because residual water initiates partial agglomeration of sucrose-containing granules during tropical storage at 30 °C/75% RH. The terminal product is a sealed laminate sachet inside a child-resistant aluminum outer pouch. Compliance references USP <905> adapted to weight variation and ICH Q1A stability zones II and IV. Sucrose-based granules are incompatible with manufacturing rooms above 50% RH without dehumidification. If dehumidification is unavailable, substitution of sucrose spheres with mannitol spheres is required. Published long-term stability data for this specific formulation is limited, so the composition is a representative starting formula requiring accelerated stability confirmation. The particle size boundary is critical: granules above 425 µm may fail dose uniformity, while fines below 75 µm may increase dust generation and line losses during sachet forming.